Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
31
AIRS Quote, Financials, Valuation and Earnings
Last price:
$5.35
Seasonality move
:
16.29%
Day range:
$5.34 - $5.82
52-week range:
$2.92 - $9.20
Dividend yield:
0%
P/E ratio:
311.08x
P/S ratio:
1.63x
P/B ratio:
3.74x
Volume:
337.8K
Avg. volume:
267.1K
1-year change:
-26.45%
Market cap:
$309.1M
Revenue:
$195.9M
EPS (TTM):
-$0.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AIRS
AirSculpt Technologies
|
$41.7M | $0.02 | -6.46% | 333.33% | -- |
|
CVS
CVS Health
|
$92.7B | $1.45 | 3.57% | -24.22% | $67.11 |
|
FPCG
First Physicians Capital Group
|
-- | -- | -- | -- | -- |
|
IQV
IQVIA Holdings
|
$3.9B | $2.81 | 1.75% | 22.53% | $249.54 |
|
UNVC
UNIVEC
|
-- | -- | -- | -- | -- |
|
WORX
SCWorx
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AIRS
AirSculpt Technologies
|
$5.34 | -- | $309.1M | 311.08x | $0.00 | 0% | 1.63x |
|
CVS
CVS Health
|
$44.36 | $67.11 | $55.8B | 11.26x | $0.67 | 6% | 0.15x |
|
FPCG
First Physicians Capital Group
|
$1,025.00 | -- | $10M | -- | $0.00 | 0% | 1.40x |
|
IQV
IQVIA Holdings
|
$197.27 | $249.54 | $35.8B | 25.89x | $0.00 | 0% | 2.37x |
|
UNVC
UNIVEC
|
$0.0026 | -- | $471.1K | -- | $0.00 | 0% | -- |
|
WORX
SCWorx
|
$1.62 | -- | $3M | -- | $0.00 | 0% | 0.67x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AIRS
AirSculpt Technologies
|
45.94% | 0.607 | 23.93% | 0.35x |
|
CVS
CVS Health
|
46.65% | 1.692 | 82.68% | 0.54x |
|
FPCG
First Physicians Capital Group
|
-- | 0.000 | -- | -- |
|
IQV
IQVIA Holdings
|
65.98% | 1.517 | 31.4% | 0.71x |
|
UNVC
UNIVEC
|
-- | 5.301 | -- | -- |
|
WORX
SCWorx
|
1.08% | 8.325 | 2.61% | 0.31x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AIRS
AirSculpt Technologies
|
$24.8M | -$3.7M | -5.02% | -9.29% | -8.73% | -$3.1M |
|
CVS
CVS Health
|
$12.6B | $2B | 3.61% | 6.68% | 0.9% | -$1.4B |
|
FPCG
First Physicians Capital Group
|
-- | -- | -- | -- | -- | -- |
|
IQV
IQVIA Holdings
|
$1.4B | $578M | 7.06% | 21.99% | 13.32% | $571M |
|
UNVC
UNIVEC
|
-- | -- | -- | -- | -- | -- |
|
WORX
SCWorx
|
$132.6K | -$393.5K | -77.97% | -80.46% | -51.8% | -$362.6K |
AirSculpt Technologies vs. Competitors
-
Which has Higher Returns AIRS or CVS?
CVS Health has a net margin of -14.2% compared to AirSculpt Technologies's net margin of 0.09%. AirSculpt Technologies's return on equity of -9.29% beat CVS Health's return on equity of 6.68%.
Company Gross Margin Earnings Per Share Invested Capital AIRSAirSculpt Technologies58.25% -$0.10 $152.7M CVSCVS Health13.16% $0.07 $140.6B -
What do Analysts Say About AIRS or CVS?
AirSculpt Technologies has a consensus price target of --, signalling upside risk potential of 26.41%. On the other hand CVS Health has an analysts' consensus of $67.11 which suggests that it could grow by 51.28%. Given that CVS Health has higher upside potential than AirSculpt Technologies, analysts believe CVS Health is more attractive than AirSculpt Technologies.
Company Buy Ratings Hold Ratings Sell Ratings AIRSAirSculpt Technologies0 4 0 CVSCVS Health12 10 0 -
Is AIRS or CVS More Risky?
AirSculpt Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CVS Health has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.901%.
-
Which is a Better Dividend Stock AIRS or CVS?
AirSculpt Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health offers a yield of 6% to investors and pays a quarterly dividend of $0.67 per share. AirSculpt Technologies pays -10.36% of its earnings as a dividend. CVS Health pays out 37.54% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AIRS or CVS?
AirSculpt Technologies quarterly revenues are $42.5M, which are smaller than CVS Health quarterly revenues of $95.4B. AirSculpt Technologies's net income of -$6M is lower than CVS Health's net income of $87M. Notably, AirSculpt Technologies's price-to-earnings ratio is 311.08x while CVS Health's PE ratio is 11.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AirSculpt Technologies is 1.63x versus 0.15x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AIRSAirSculpt Technologies1.63x 311.08x $42.5M -$6M CVSCVS Health0.15x 11.26x $95.4B $87M
-
Which has Higher Returns AIRS or FPCG?
First Physicians Capital Group has a net margin of -14.2% compared to AirSculpt Technologies's net margin of --. AirSculpt Technologies's return on equity of -9.29% beat First Physicians Capital Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AIRSAirSculpt Technologies58.25% -$0.10 $152.7M FPCGFirst Physicians Capital Group-- -- -- -
What do Analysts Say About AIRS or FPCG?
AirSculpt Technologies has a consensus price target of --, signalling upside risk potential of 26.41%. On the other hand First Physicians Capital Group has an analysts' consensus of -- which suggests that it could fall by --. Given that AirSculpt Technologies has higher upside potential than First Physicians Capital Group, analysts believe AirSculpt Technologies is more attractive than First Physicians Capital Group.
Company Buy Ratings Hold Ratings Sell Ratings AIRSAirSculpt Technologies0 4 0 FPCGFirst Physicians Capital Group0 0 0 -
Is AIRS or FPCG More Risky?
AirSculpt Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Physicians Capital Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AIRS or FPCG?
AirSculpt Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Physicians Capital Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AirSculpt Technologies pays -10.36% of its earnings as a dividend. First Physicians Capital Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AIRS or FPCG?
AirSculpt Technologies quarterly revenues are $42.5M, which are larger than First Physicians Capital Group quarterly revenues of --. AirSculpt Technologies's net income of -$6M is higher than First Physicians Capital Group's net income of --. Notably, AirSculpt Technologies's price-to-earnings ratio is 311.08x while First Physicians Capital Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AirSculpt Technologies is 1.63x versus 1.40x for First Physicians Capital Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AIRSAirSculpt Technologies1.63x 311.08x $42.5M -$6M FPCGFirst Physicians Capital Group1.40x -- -- --
-
Which has Higher Returns AIRS or IQV?
IQVIA Holdings has a net margin of -14.2% compared to AirSculpt Technologies's net margin of 7.32%. AirSculpt Technologies's return on equity of -9.29% beat IQVIA Holdings's return on equity of 21.99%.
Company Gross Margin Earnings Per Share Invested Capital AIRSAirSculpt Technologies58.25% -$0.10 $152.7M IQVIQVIA Holdings35.37% $1.55 $20.5B -
What do Analysts Say About AIRS or IQV?
AirSculpt Technologies has a consensus price target of --, signalling upside risk potential of 26.41%. On the other hand IQVIA Holdings has an analysts' consensus of $249.54 which suggests that it could grow by 26.5%. Given that IQVIA Holdings has higher upside potential than AirSculpt Technologies, analysts believe IQVIA Holdings is more attractive than AirSculpt Technologies.
Company Buy Ratings Hold Ratings Sell Ratings AIRSAirSculpt Technologies0 4 0 IQVIQVIA Holdings15 4 0 -
Is AIRS or IQV More Risky?
AirSculpt Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IQVIA Holdings has a beta of 1.486, suggesting its more volatile than the S&P 500 by 48.559%.
-
Which is a Better Dividend Stock AIRS or IQV?
AirSculpt Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IQVIA Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AirSculpt Technologies pays -10.36% of its earnings as a dividend. IQVIA Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AIRS or IQV?
AirSculpt Technologies quarterly revenues are $42.5M, which are smaller than IQVIA Holdings quarterly revenues of $3.9B. AirSculpt Technologies's net income of -$6M is lower than IQVIA Holdings's net income of $285M. Notably, AirSculpt Technologies's price-to-earnings ratio is 311.08x while IQVIA Holdings's PE ratio is 25.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AirSculpt Technologies is 1.63x versus 2.37x for IQVIA Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AIRSAirSculpt Technologies1.63x 311.08x $42.5M -$6M IQVIQVIA Holdings2.37x 25.89x $3.9B $285M
-
Which has Higher Returns AIRS or UNVC?
UNIVEC has a net margin of -14.2% compared to AirSculpt Technologies's net margin of --. AirSculpt Technologies's return on equity of -9.29% beat UNIVEC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AIRSAirSculpt Technologies58.25% -$0.10 $152.7M UNVCUNIVEC-- -- -- -
What do Analysts Say About AIRS or UNVC?
AirSculpt Technologies has a consensus price target of --, signalling upside risk potential of 26.41%. On the other hand UNIVEC has an analysts' consensus of -- which suggests that it could fall by --. Given that AirSculpt Technologies has higher upside potential than UNIVEC, analysts believe AirSculpt Technologies is more attractive than UNIVEC.
Company Buy Ratings Hold Ratings Sell Ratings AIRSAirSculpt Technologies0 4 0 UNVCUNIVEC0 0 0 -
Is AIRS or UNVC More Risky?
AirSculpt Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison UNIVEC has a beta of 0.131, suggesting its less volatile than the S&P 500 by 86.927%.
-
Which is a Better Dividend Stock AIRS or UNVC?
AirSculpt Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UNIVEC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AirSculpt Technologies pays -10.36% of its earnings as a dividend. UNIVEC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AIRS or UNVC?
AirSculpt Technologies quarterly revenues are $42.5M, which are larger than UNIVEC quarterly revenues of --. AirSculpt Technologies's net income of -$6M is higher than UNIVEC's net income of --. Notably, AirSculpt Technologies's price-to-earnings ratio is 311.08x while UNIVEC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AirSculpt Technologies is 1.63x versus -- for UNIVEC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AIRSAirSculpt Technologies1.63x 311.08x $42.5M -$6M UNVCUNIVEC-- -- -- --
-
Which has Higher Returns AIRS or WORX?
SCWorx has a net margin of -14.2% compared to AirSculpt Technologies's net margin of -55.94%. AirSculpt Technologies's return on equity of -9.29% beat SCWorx's return on equity of -80.46%.
Company Gross Margin Earnings Per Share Invested Capital AIRSAirSculpt Technologies58.25% -$0.10 $152.7M WORXSCWorx17.45% -$0.27 $4.5M -
What do Analysts Say About AIRS or WORX?
AirSculpt Technologies has a consensus price target of --, signalling upside risk potential of 26.41%. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that AirSculpt Technologies has higher upside potential than SCWorx, analysts believe AirSculpt Technologies is more attractive than SCWorx.
Company Buy Ratings Hold Ratings Sell Ratings AIRSAirSculpt Technologies0 4 0 WORXSCWorx0 0 0 -
Is AIRS or WORX More Risky?
AirSculpt Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SCWorx has a beta of 2.792, suggesting its more volatile than the S&P 500 by 179.246%.
-
Which is a Better Dividend Stock AIRS or WORX?
AirSculpt Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AirSculpt Technologies pays -10.36% of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AIRS or WORX?
AirSculpt Technologies quarterly revenues are $42.5M, which are larger than SCWorx quarterly revenues of $759.7K. AirSculpt Technologies's net income of -$6M is lower than SCWorx's net income of -$425K. Notably, AirSculpt Technologies's price-to-earnings ratio is 311.08x while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AirSculpt Technologies is 1.63x versus 0.67x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AIRSAirSculpt Technologies1.63x 311.08x $42.5M -$6M WORXSCWorx0.67x -- $759.7K -$425K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
